BRIACELL THERAPEUTICS CORP. : Regulation FD Disclosure (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 18, 2023, BriaCell Therapeutics Corp. (the "Company") issued a press release announcing that that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding the Company's lead clinical candidate, Bria-IMT™, in combination with a checkpoint inhibitor in advanced metastatic breast cancer.

A copy of the press release is attached as Exhibit 99.1.

The information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses